Ratings EL.En. S.p.A.

Equities

ELN

IT0005453250

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-05-07 am EDT			5-day change	1st Jan Change
11.73 ^EUR	0.00%		-0.85%	+20.31%

Mar. 15	Transcript : EL.En. S.p.A., 2023 Earnings Call, Mar 15, 2024
Mar. 14	EL.En. S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
For several months, analysts have been revising their EPS estimates roughly upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
EL.EN. S.P.A.	+20.31%	1.01B		B+
SISRAM MEDICAL LTD	-25.29%	237M		-
LASEROPTEK CO., LTD.	-28.57%	84.13M	-	-
CUTERA, INC.	-21.99%	57.09M		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes